Related Experiment Video

Updated: Nov 9, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.1K

Targeted delivery of thrombolytic enzymes

Young M Kwon1

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, Health Professions Division, Nova Southeastern University 3200 S. University Dr. Fort Lauderdale, FL 33328.

Bioimpacts : BI
|April 12, 2021
PubMed

Insights

Developing safer thrombolytic agents is crucial for treating thromboembolic conditions. Novel nanoscale drug carriers offer a promising approach to improve the safety and efficacy of thrombolytic enzyme delivery.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Pharmacology

Background:

  • Thrombolytic agents are vital for treating thromboembolic conditions but have significant side effects.
  • Current therapeutic strategies necessitate the development of safer alternatives.

Discussion:

  • Novel nanoscale drug delivery systems are being designed to improve thrombolytic therapy.
  • These systems leverage thrombosis-specific pathophysiologic signatures and external triggers for targeted delivery.
  • Nanoscale carriers aim to mitigate the fatal side effects associated with conventional thrombolytic agents.

Key Insights:

  • Nanoscale carriers can enhance the targeted delivery of thrombolytic enzymes.
  • Exploiting pathophysiologic signatures of thrombosis offers a strategy for localized drug action.
  • External triggers can provide additional control over drug release and therapeutic effect.

Outlook:

  • While still in early stages, nanoscale therapeutics hold significant promise for future clinical applications.
  • Further research and development are needed to translate these nanoscale systems to the bedside.
  • The integration of nanotechnology in thrombolysis represents a hopeful advancement in cardiovascular medicine.
Keywords:
NanocarriersTargeted deliveryThrombolyticstPA

More Related Videos

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.9K
Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.4K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
94
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
99
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
819